Abstract Background The tumor microenvironment plays a crucial role in determining the prognosis of tumors. Fc gamma receptor IIa (FcγRIIa), one of the three subtypes of FcγRII, is expressed on platelets and immunocytes such as macrophages and neutrophils. These cellular elements collectively contribute to the tumor microenvironment. Previous research has indicated that FcγRIIa activates platelets and inflammatory cells, thus participating in tumor growth and metastasis. Nonetheless, limited information is available regarding FcγRIIa levels in most cancer types. This study aimed to detect serum FcγRIIa in 333 patients with non-small cell lung cancer (NSCLC) and 100 healthy individuals, and to explore the relationship between serum FcγRIIa levels and clinical outcomes in patients with NSCLC. Methods Serum samples from 333 patients with stage I–IV NSCLC and 100 healthy volunteers were analyzed using ELISA. The clinical and laboratory data underwent statistical analysis. Results Circulating FcγRIIa levels were markedly increased in patients with NSCLC, especially in advanced pathologic stages.ROC curve analysis yielded an AUC of 0.7713 (95% CI: 0.7132–0.8264), with an optimal cutoff value of 2115.88 pg/mL based on the Youden index (sensitivity: 60.06%, specificity: 86.00%). Notably, 13% of healthy controls showed FcγRIIa levels above the cutoff, suggesting that elevated FcγRIIa may partially reflect systemic inflammatory status. Survival analysis in 333 patients with NSCLC showed markedly shorter overall survival in FcγRIIa-positive cases. Serum FcγRIIa levels were further identified to be significantly associated with metastatic status. Conclusion This study demonstrated that circulating FcγRIIa levels rise along with tumor progression and may serve as a potential complementary prognostic indicator in metastatic NSCLC, though these findings require validation in prospective cohorts with comprehensive adjustment for inflammatory markers and treatment regimens.
Wang et al. (Sun,) studied this question.